• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Rating the comparative efficacy of state-level cannabis policies on recreational cannabis markets in the United States.评估美国州级层面的娱乐用大麻政策对娱乐用大麻市场的相对效果。
Int J Drug Policy. 2022 Aug;106:103744. doi: 10.1016/j.drugpo.2022.103744. Epub 2022 May 25.
2
Community-level policy responses to state marijuana legalization in Washington State.华盛顿州针对该州大麻合法化的社区层面政策应对措施。
Int J Drug Policy. 2017 Apr;42:102-108. doi: 10.1016/j.drugpo.2017.02.010. Epub 2017 Mar 30.
3
Efficacy and the strength of evidence of U.S. alcohol control policies.美国酒精控制政策的效果和证据强度。
Am J Prev Med. 2013 Jul;45(1):19-28. doi: 10.1016/j.amepre.2013.03.008.
4
The Cannabis Policy Scale: A New Research and Surveillance Tool for U.S. States.《大麻政策量表:美国各州的一项新研究和监测工具》。
J Stud Alcohol Drugs. 2022 Nov;83(6):829-838. doi: 10.15288/jsad.21-00462.
5
U.S. State approaches to cannabis licensing.美国各州的大麻许可发放方式。
Int J Drug Policy. 2022 Aug;106:103755. doi: 10.1016/j.drugpo.2022.103755. Epub 2022 Jun 9.
6
Changes in alcohol and cigarette consumption in response to medical and recreational cannabis legalization: Evidence from U.S. state tax receipt data.医疗和娱乐用大麻合法化对酒精和香烟消费的影响变化:来自美国州税收收据数据的证据。
Int J Drug Policy. 2020 Jan;75:102585. doi: 10.1016/j.drugpo.2019.10.011. Epub 2019 Nov 15.
7
How should policymakers regulate the tetrahydrocannabinol content of cannabis products in a legal market?政策制定者应如何在合法市场中监管大麻产品的四氢大麻酚含量?
Addiction. 2023 Jun;118(6):998-1003. doi: 10.1111/add.16135. Epub 2023 Feb 2.
8
Prices and Purchase Sources for Dried Cannabis Flower in the United States, 2019-2020.2019-2020 年美国干大麻花的价格和采购来源。
Cannabis Cannabinoid Res. 2023 Oct;8(5):923-932. doi: 10.1089/can.2021.0232. Epub 2022 Apr 1.
9
Cannabis consumers' preferences for legal and illegal cannabis: evidence from a discrete choice experiment.大麻消费者对合法和非法大麻的偏好:来自离散选择实验的证据。
BMC Public Health. 2024 Sep 4;24(1):2397. doi: 10.1186/s12889-024-19640-1.
10
Marijuana Policy Bundles in the American States Over Time and Their Impact on the Use of Marijuana and Other Drugs.美国各州的大麻政策包随时间的变化及其对大麻和其他药物使用的影响。
Eval Rev. 2022 Apr;46(2):165-199. doi: 10.1177/0193841X221077795. Epub 2022 Feb 23.

引用本文的文献

1
Cannabis Policies, Cannabis, and Opioids in Suicide and Undetermined Intent Death.大麻政策、大麻与自杀及意图不明死亡中的阿片类药物
Am J Prev Med. 2025 Mar;68(3):475-484. doi: 10.1016/j.amepre.2024.11.009. Epub 2024 Nov 28.
2
The association between state cannabis policies and cannabis use among adults and youth, United States, 2002-2019.2002 - 2019年美国各州大麻政策与成年人及青少年大麻使用之间的关联
Addiction. 2025 Jan;120(1):164-170. doi: 10.1111/add.16663. Epub 2024 Sep 19.
3
Effects of recent cannabis consumption on eye-tracking and pupillometry.近期吸食大麻对眼动追踪和瞳孔测量的影响。
Front Neurosci. 2024 Apr 9;18:1358491. doi: 10.3389/fnins.2024.1358491. eCollection 2024.
4
Relationships Between Alcohol and Cannabis Policies in U.S. States, 1999-2019.美国各州 1999-2019 年的酒精和大麻政策关系。
J Stud Alcohol Drugs. 2024 Mar;85(2):254-260. doi: 10.15288/jsad.23-00035. Epub 2023 Dec 26.

本文引用的文献

1
Lower-Risk Cannabis Use Guidelines (LRCUG) for reducing health harms from non-medical cannabis use: A comprehensive evidence and recommendations update.降低非医疗用大麻使用健康危害的低风险大麻使用指南(LRCUG):全面的证据和建议更新。
Int J Drug Policy. 2022 Jan;99:103381. doi: 10.1016/j.drugpo.2021.103381. Epub 2021 Aug 28.
2
How medical are states' medical cannabis policies?: Proposing a standardized scale.各州的医用大麻政策有多“医学”?:提出一个标准化的评估尺度。
Int J Drug Policy. 2021 Aug;94:103202. doi: 10.1016/j.drugpo.2021.103202. Epub 2021 Mar 23.
3
Government monopoly as an instrument for public health and welfare: Lessons for cannabis from experience with alcohol monopolies.政府垄断作为公共卫生和福利的工具:从酒精垄断经验中汲取大麻的教训。
Int J Drug Policy. 2019 Dec;74:223-228. doi: 10.1016/j.drugpo.2019.10.008. Epub 2019 Nov 4.
4
Early evidence of the impact of cannabis legalization on cannabis use, cannabis use disorder, and the use of other substances: Findings from state policy evaluations.大麻合法化对大麻使用、大麻使用障碍和其他物质使用影响的早期证据:州政策评估结果。
Am J Drug Alcohol Abuse. 2019;45(6):644-663. doi: 10.1080/00952990.2019.1669626. Epub 2019 Oct 11.
5
Marijuana Regulatory Frameworks in Four US States: An Analysis Against a Public Health Standard.美国四个州的大麻监管框架:基于公共卫生标准的分析。
Am J Public Health. 2018 Jul;108(7):914-923. doi: 10.2105/AJPH.2018.304401.
6
Trends in and correlates of medical marijuana use among adults in the United States.美国成年人中医用大麻使用的趋势及相关因素。
Drug Alcohol Depend. 2018 May 1;186:120-129. doi: 10.1016/j.drugalcdep.2018.01.022. Epub 2018 Mar 14.
7
A new approach to formulating and appraising drug policy: A multi-criterion decision analysis applied to alcohol and cannabis regulation.一种制定和评估药物政策的新方法:多准则决策分析在酒精和大麻管制中的应用。
Int J Drug Policy. 2018 Jun;56:144-152. doi: 10.1016/j.drugpo.2018.01.019. Epub 2018 Feb 17.
8
Medical Marijuana and Marijuana Legalization.医用大麻与大麻合法化。
Annu Rev Clin Psychol. 2017 May 8;13:397-419. doi: 10.1146/annurev-clinpsy-032816-045128.
9
Understanding and learning from the diversification of cannabis supply laws.理解大麻供应法律的多样化并从中学习。
Addiction. 2017 Jul;112(7):1128-1135. doi: 10.1111/add.13623. Epub 2016 Nov 27.
10
A Public Health Framework for Legalized Retail Marijuana Based on the US Experience: Avoiding a New Tobacco Industry.基于美国经验的合法零售大麻公共卫生框架:避免新烟草行业的出现。
PLoS Med. 2016 Sep 27;13(9):e1002131. doi: 10.1371/journal.pmed.1002131. eCollection 2016 Sep.

评估美国州级层面的娱乐用大麻政策对娱乐用大麻市场的相对效果。

Rating the comparative efficacy of state-level cannabis policies on recreational cannabis markets in the United States.

机构信息

Boston University, 715 Albany St., Boston, MA 02118, USA.

University of Southern California, 650 Childs Way, Los Angeles, CA 90089, USA.

出版信息

Int J Drug Policy. 2022 Aug;106:103744. doi: 10.1016/j.drugpo.2022.103744. Epub 2022 May 25.

DOI:10.1016/j.drugpo.2022.103744
PMID:35636068
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11563470/
Abstract

BACKGROUND

Cannabis policy is developing faster than empirical evidence about policy effects. With a panel of experts in substance use policy development and research, we identified key cannabis policies and their provisions enacted by U.S. states; rated their theoretical efficacy in a restrictive form for reducing problematic use and impaired driving in the context of a recreational cannabis market as judged by experts; and rated the strength of evidence for each policy.

METHODS

Using a modified Delphi approach, 9 panelists rated the comparative efficacy of 18 state cannabis policies for reducing youth use of cannabis, excessive cannabis use among the general population, and cannabis-impaired driving. Each outcome was rated separately using a Likert scale, and panelists also rated the strength of evidence supporting each efficacy rating. Investigators provided descriptions of each policy so that the nine panelists had similar conceptions of each policy.

RESULTS

State monopoly (state owns all production, manufacturing, wholesale, and retail operations) was rated as the most effective policy for all three outcome areas. Restrictions on retail physical availability, taxes, retail price restrictions, and retail operations restrictions were also highly rated for all three outcomes. Policies regulating cannabis businesses and products were judged more effective than policies targeting consumer use and behavior. Panelists reported there was little or no direct evidence from the cannabis policy literature for most of the included policies.

CONCLUSION

These ratings can facilitate research as well as policy-making decisions. A relatively small number of policies were judged to be highly effective across all three domains, indicating that for the most part adult excessive use, youth use, and impaired driving can all be reduced with the same set of policies; these policies tended to target the behaviors of businesses rather than consumers. The low levels of direct evidence available to inform policy ratings, as reported by the policy panelists, makes clear the need for ongoing and sustained cannabis policy research.

摘要

背景

大麻政策的发展速度超过了政策效果的经验证据。我们组织了一个由物质使用政策制定和研究方面的专家组成的小组,确定了美国各州颁布的关键大麻政策及其规定;根据专家判断,在娱乐大麻市场背景下,以限制形式评估这些政策在减少问题性使用和驾驶障碍方面的理论效果;并对每项政策的证据强度进行了评级。

方法

使用改良 Delphi 方法,9 名小组成员对 18 项州大麻政策在减少青少年大麻使用、普通人群中过度使用大麻和大麻影响驾驶方面的相对效果进行了评估。每个结果都使用李克特量表进行单独评估,小组成员还对每项效果评估的证据强度进行了评级。调查人员对每项政策进行了描述,以便 9 名小组成员对每项政策都有类似的理解。

结果

州垄断(州拥有所有生产、制造、批发和零售业务)被评为所有三个结果领域最有效的政策。对零售物理可用性、税收、零售价格限制和零售业务限制的限制也被高度评价,适用于所有三个结果。监管大麻企业和产品的政策被认为比针对消费者使用和行为的政策更有效。小组成员报告说,大多数纳入的政策在大麻政策文献中几乎没有或没有直接证据。

结论

这些评级可以促进研究和决策。少数几项政策被评为在所有三个领域都非常有效,这表明在大多数情况下,成年人过度使用、青少年使用和驾驶障碍都可以通过同一套政策来减少;这些政策往往针对企业的行为,而不是消费者的行为。政策小组成员报告说,可用于为政策评级提供信息的直接证据水平较低,这清楚地表明需要持续进行和维持大麻政策研究。